WO2005019200A3 - Derives d'arylpiperidine utilises en tant qu'antagonistes d'integrine vla-1 et utilisations de ceux-ci - Google Patents

Derives d'arylpiperidine utilises en tant qu'antagonistes d'integrine vla-1 et utilisations de ceux-ci Download PDF

Info

Publication number
WO2005019200A3
WO2005019200A3 PCT/US2004/026206 US2004026206W WO2005019200A3 WO 2005019200 A3 WO2005019200 A3 WO 2005019200A3 US 2004026206 W US2004026206 W US 2004026206W WO 2005019200 A3 WO2005019200 A3 WO 2005019200A3
Authority
WO
WIPO (PCT)
Prior art keywords
vla
integrin antagonists
piperidine derivatives
aryl piperidine
integrin
Prior art date
Application number
PCT/US2004/026206
Other languages
English (en)
Other versions
WO2005019200A2 (fr
Inventor
Steven A Boyd
Jason Demeese
Indrani Gunawardana
Irina C Jacobson
Yvan Lehuerou
Mark L Lupher Jr
Martin Mclaughlin
Scott Miller
Allen Thomas
Eugene Thorsett
Rui Xu
Matthew Yanik
Gan Zhang
Original Assignee
Icos Corp
Steven A Boyd
Jason Demeese
Indrani Gunawardana
Irina C Jacobson
Yvan Lehuerou
Mark L Lupher Jr
Martin Mclaughlin
Scott Miller
Allen Thomas
Eugene Thorsett
Rui Xu
Matthew Yanik
Gan Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp, Steven A Boyd, Jason Demeese, Indrani Gunawardana, Irina C Jacobson, Yvan Lehuerou, Mark L Lupher Jr, Martin Mclaughlin, Scott Miller, Allen Thomas, Eugene Thorsett, Rui Xu, Matthew Yanik, Gan Zhang filed Critical Icos Corp
Publication of WO2005019200A2 publication Critical patent/WO2005019200A2/fr
Publication of WO2005019200A3 publication Critical patent/WO2005019200A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés qui sont des antagonistes d'intégrine VLA-1. L'invention concerne également des compositions contenant lesdits composés et des procédés d'utilisation de ceux-ci dans le traitement de maladies dont la médiation est assurée, au moins en partie, par l'intégrine VLA-1.
PCT/US2004/026206 2003-08-14 2004-08-12 Derives d'arylpiperidine utilises en tant qu'antagonistes d'integrine vla-1 et utilisations de ceux-ci WO2005019200A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49574003P 2003-08-14 2003-08-14
US60/495,740 2003-08-14

Publications (2)

Publication Number Publication Date
WO2005019200A2 WO2005019200A2 (fr) 2005-03-03
WO2005019200A3 true WO2005019200A3 (fr) 2008-01-03

Family

ID=34215939

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/026206 WO2005019200A2 (fr) 2003-08-14 2004-08-12 Derives d'arylpiperidine utilises en tant qu'antagonistes d'integrine vla-1 et utilisations de ceux-ci

Country Status (1)

Country Link
WO (1) WO2005019200A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946278B2 (en) 2007-02-07 2015-02-03 Glaxosmithkline Llc Inhibitors of AkT activity

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2557768T3 (es) 1999-06-01 2016-01-28 Biogen Ma Inc. Un anticuerpo monoclonal bloqueante frente a VLA-1 y su uso para el tratamiento de trastornos inflamatorios
IL158376A0 (en) 2001-04-13 2004-05-12 Biogen Inc Antibodies to vla-1
ES2398934T3 (es) 2005-03-28 2013-03-22 Toyama Chemical Co., Ltd. Proceso de la producción de1-(3-(2-(1-benzotiofen-5-il)etoxi)propil)acetidin-ol o sales del mismo
WO2006130493A2 (fr) * 2005-05-31 2006-12-07 Vertex Pharmaceuticals Incorporated Heterocycles utiles comme modulateurs de canaux ioniques
AU2015227462B2 (en) * 2006-05-25 2017-11-02 Biogen Ma Inc. Methods of Treating Stroke
PL2034830T3 (pl) * 2006-05-25 2015-04-30 Biogen Ma Inc Przeciwciało anty-VLA-1 do leczenia udaru
AU2013204572B2 (en) * 2006-05-25 2015-06-18 Biogen Ma Inc. Methods of Treating Stroke
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
US20130096160A1 (en) * 2010-04-14 2013-04-18 Secretary, Department Of Health And Human Services Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
US10316095B2 (en) 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations
CA2876382A1 (fr) 2012-06-14 2013-12-19 Daiichi Sankyo Company, Limited Derive de piperidinylpyrazolopyridine
US9643957B2 (en) 2012-12-11 2017-05-09 Takeda Pharmaceutical Company Limited Heterocyclic compounds having cholesterol 24-hydroxylase activity
CN111148743B (zh) 2017-10-06 2023-12-15 福马治疗有限公司 抑制泛素特异性肽酶30
CA3110113A1 (fr) 2018-10-05 2020-04-09 Forma Therapeutics, Inc. Pyrrolines fusionnees qui agissent en tant qu'inhibiteurs de la protease 30 (usp30) specifique de l'ubiquitine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291453B1 (en) * 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US20020019419A1 (en) * 2000-06-22 2002-02-14 De Laszlo Stephen E. Substituted isonipecotyl derivatives as inhibitors of cell adhesion
US6486154B1 (en) * 1997-07-29 2002-11-26 Zeneca Limited (Hetero) aryl-sulfonamide derivatives, their preparation and their use as factor XA inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486154B1 (en) * 1997-07-29 2002-11-26 Zeneca Limited (Hetero) aryl-sulfonamide derivatives, their preparation and their use as factor XA inhibitors
US6291453B1 (en) * 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US20020019419A1 (en) * 2000-06-22 2002-02-14 De Laszlo Stephen E. Substituted isonipecotyl derivatives as inhibitors of cell adhesion

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. E. GUTTERIDGE ET. AL.: "N-(3-Phenylsulfonyl-3-piperidonyl)-phenylalanine Derivatives as Potent, Selective, VLA-4 Antagonists.", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 13, no. 5, 10 March 2003 (2003-03-10), pages 885 - 890, XP001179737 *
K. SAGI ET. AL: "Rational Design, Synthesis and Strucutre-Activity Relationships of Novel Factor Xa Inhibitors. 2-(Substituted-4-amidinophenyl)-pyruvic and propionic Acids", JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, no. 18, 8 May 2003 (2003-05-08), pages 1845 - 1857, XP002319434 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946278B2 (en) 2007-02-07 2015-02-03 Glaxosmithkline Llc Inhibitors of AkT activity

Also Published As

Publication number Publication date
WO2005019200A2 (fr) 2005-03-03

Similar Documents

Publication Publication Date Title
WO2005016883A3 (fr) Derives d'acrylamide servant d'antagonistes de l'integrine vla-1, et leurs utilisations
WO2008064351A3 (fr) (r)-n-stéréoisomères d'analogues 4,5-époxy-morphinanium saturé en position 7 et 8
WO2006044362A3 (fr) Antagonistes du recepteur 1 de n-sulfonylpiperidine cannabinoide
WO2006034039A3 (fr) Morphinanes substitues et leurs procedes d'utilisation
WO2006085149A3 (fr) Methodes et compositions de traitement de maladies liees a l'amyloide
WO2005019200A3 (fr) Derives d'arylpiperidine utilises en tant qu'antagonistes d'integrine vla-1 et utilisations de ceux-ci
IL216579A (en) History of aminocyclohexyl ether and pharmacy preparations containing them
WO2004011611A3 (fr) Anticorps anti-taci et utilisations de ceux-ci
WO2007081974A3 (fr) Traitement de l'hépatite virale
WO2005110994A8 (fr) Derives de pyrazolyl uree substitues utiles dans le traitement du cancer
WO2004014322A3 (fr) Compositions immunomodulatrices, leurs methodes de preparation et utilisation
FR2841900B1 (fr) Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
IL168056A0 (en) Selected cgrp antagonists, method for production and use thereof as medicament
WO2002096361A3 (fr) Derives de 5-aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone utilises comme inhibiteurs de kinase
WO2006037024A3 (fr) Sels de decitabine
WO2004009062A3 (fr) Antagonistes du recepteur nmda et leur utilisation pour inhiber l'hyperphosphorylation de la proteine associee aux microtubules tau
WO2004113277A8 (fr) Procedes et compositions de traitement de maladies associees aux amyloides
WO2005030188A3 (fr) Derives de phenyl-piperazine en tant que modulateurs des recepteurs muscariniques
WO2007109279A3 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
WO2005085188A3 (fr) Composes et procedes pour la therapie antitumorale
IL172542A0 (en) 2-hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide
WO2005037470A3 (fr) Nanoparticules encapsulees, produits contenant ces nanoparticules et procedes pour les utiliser
WO2004112704A3 (fr) Composes de piperidine substitues et procedes d'utilisation associes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase